Cancer diagnostics and therapies have improved steadily over the last few decades,
markedly increasing life expectancy for patients at all ages. However, conventional and …

Although effective anti-neoplastic agents, anthracyclines are limited by their well recognized
and pervasive cardiotoxic effects. The incidence of late progressive cardiovascular disease …

Background: Anthracycline-induced cardiotoxicity has led to the adoption of empirical dose
limits that may restrict continued use of anthracyclines among patients who might benefit …

This article summarizes the views of an expert meeting of cardiologists and oncologists on
the use of dexrazoxane in anthracycline-based chemotherapy. Anthracycline-induced …

Anthracyclines are a well-known cause of cardiotoxicity, but a number of other drugs used to
treat cancer can also result in cardiac and cardiovascular adverse effects. Cardiotoxicity can …

Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer.
Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer …

Background Cardiotoxicity associated with anthracycline-based chemotherapies has limited
their use in patients with preexisting cardiomyopathy or heart failure. Dexrazoxane protects …

Anthracycline-based chemotherapeutics have long been recognized as effective agents for
treating a wide range of malignancies. However, their use is not without significant adverse …

Chemotherapy drugs have been reported to cause cardiac side effects including
cardiomyopathy, ischemia, arrhythmias, and myocardial necrosis. Most important in terms of …

Introduction: With advances in clinical oncology, the burden of morbidity and mortality for
cancer survivors due to the cardiac side effects of the chemotherapy is steadily increasing …